229 related articles for article (PubMed ID: 32761328)
1. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
Meijer TS; Burgmans MC; de Leede EM; de Geus-Oei LF; Boekestijn B; Handgraaf HJM; Hilling DE; Lutjeboer J; Vuijk J; Martini CH; van Erkel AR; van der Meer RW; Tijl FGJ; Speetjens FM; Kapiteijn E; Vahrmeijer AL
Ann Surg Oncol; 2021 Feb; 28(2):1130-1141. PubMed ID: 32761328
[TBL] [Abstract][Full Text] [Related]
2. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer.
Meijer TS; Dieters JHN; de Leede EM; de Geus-Oei LF; Vuijk J; Martini CH; van Erkel AR; Lutjeboer J; van der Meer RW; Tijl FGJ; Kapiteijn E; Vahrmeijer AL; Burgmans MC
PLoS One; 2022; 17(1):e0261939. PubMed ID: 35025911
[TBL] [Abstract][Full Text] [Related]
4. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
5. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
[TBL] [Abstract][Full Text] [Related]
6. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
[TBL] [Abstract][Full Text] [Related]
8. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
9. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
[TBL] [Abstract][Full Text] [Related]
12. Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers.
Veelken R; Maiwald B; Strocka S; Petersen TO; Moche M; Ebel S; Denecke T; Rehak M; Struck MF; Forstmeyer D; Rademacher S; Seehofer D; Berg T; van Bömmel F
Cardiovasc Intervent Radiol; 2022 Feb; 45(2):218-222. PubMed ID: 34716470
[TBL] [Abstract][Full Text] [Related]
13. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
[TBL] [Abstract][Full Text] [Related]
14. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C
Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
[TBL] [Abstract][Full Text] [Related]
16. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
Modi S; Gibson T; Vigneswaran G; Patel S; Wheater M; Karydis I; Gupta S; Takhar A; Pearce N; Ottensmeier C; Stedman B
Melanoma Res; 2022 Apr; 32(2):103-111. PubMed ID: 35254333
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.
Tong TML; Fiocco M; van Duijn-de Vreugd JJ; Lutjeboer J; Speetjens FM; Tijl FGJ; Sitsen ME; Zoethout RWM; Martini CH; Vahrmeijer AL; van der Meer RW; van Rijswijk CSP; van Erkel AR; Kapiteijn E; Burgmans MC
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):741-750. PubMed ID: 38587534
[TBL] [Abstract][Full Text] [Related]
18. Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma.
Meijer TS; Geus-Oei LF; Martini CH; Tijl FGJ; Sitsen ME; Erkel ARV; Meer RWV; Kapiteijn E; Vahrmeijer AL; Burgmans MC
Diagn Interv Radiol; 2019 Nov; 25(6):451-458. PubMed ID: 31650973
[TBL] [Abstract][Full Text] [Related]
19. ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma.
Meijer TS; Burgmans MC
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):820-821. PubMed ID: 32683632
[No Abstract] [Full Text] [Related]
20. [Isolated liver perfusion with melphalan followed by pembrolizumab therapy for unresectable metastases of uveal melanoma to the liver].
Kaprin AD; Ivanov SA; Unguryan VM; Kazantsev AN; Belov YV
Khirurgiia (Mosk); 2023; (7):94-99. PubMed ID: 37379411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
